Abstract
With the continued rise in antibiotic-resistant bacteria, there is an immense need for the development of new therapeutic agents. Host-defense peptides (HDPs) offer a unique alternative to many of the current approved antibiotics. By targeting the host rather than the pathogen, HDPs offer several benefits over traditional small molecule drug treatments, such as a slower propensity towards resistance, broad-spectrum activity and lower risk of patients developing sepsis. However, natural peptide structures have many disadvantages as well, including susceptibility to proteolytic degradation, significant costs of synthesis and host toxicity. For this reason, much work has been done to examine peptidomimetic structures, in the hopes of finding a structure with all of the desired qualities of an antibiotic drug. Recently, this research has included synthetic constructs that mimic the behavior of HDPs but have no structural similarity to peptides. This review article focuses on the progression of this field of research, beginning with an analysis of a few prominent examples of natural HDPs and moving on to describe how the information learned by studying them have led to the current design platforms.
Keywords: Antimicrobial, Host-defense peptide, Immunomodulation, Innate-defense regulator, Peptidomimetic, SMAMP.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Recent Advances in Peptide Immunomodulators
Volume: 16 Issue: 2
Author(s): Breanna L. Zerfas and Jianmin Gao
Affiliation:
Keywords: Antimicrobial, Host-defense peptide, Immunomodulation, Innate-defense regulator, Peptidomimetic, SMAMP.
Abstract: With the continued rise in antibiotic-resistant bacteria, there is an immense need for the development of new therapeutic agents. Host-defense peptides (HDPs) offer a unique alternative to many of the current approved antibiotics. By targeting the host rather than the pathogen, HDPs offer several benefits over traditional small molecule drug treatments, such as a slower propensity towards resistance, broad-spectrum activity and lower risk of patients developing sepsis. However, natural peptide structures have many disadvantages as well, including susceptibility to proteolytic degradation, significant costs of synthesis and host toxicity. For this reason, much work has been done to examine peptidomimetic structures, in the hopes of finding a structure with all of the desired qualities of an antibiotic drug. Recently, this research has included synthetic constructs that mimic the behavior of HDPs but have no structural similarity to peptides. This review article focuses on the progression of this field of research, beginning with an analysis of a few prominent examples of natural HDPs and moving on to describe how the information learned by studying them have led to the current design platforms.
Export Options
About this article
Cite this article as:
Zerfas L. Breanna and Gao Jianmin, Recent Advances in Peptide Immunomodulators, Current Topics in Medicinal Chemistry 2016; 16 (2) . https://dx.doi.org/10.2174/1568026615666150701114638
DOI https://dx.doi.org/10.2174/1568026615666150701114638 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Analysis of Interleukin-1 Receptor Antagonist Variable Number Tandem Repeat Variant in Recurrent Aphthous Stomatitis
Endocrine, Metabolic & Immune Disorders - Drug Targets Cetuximab: Its Use in Combination with Radiation Therapy and Chemotherapy in the Multimodality Treatment of Head and Neck Cancer
Recent Patents on Anti-Cancer Drug Discovery Molecular Link between Intravascular Hemolysis and Vascular Occlusion in Sickle Cell Disease
Current Vascular Pharmacology Application of Carbon Monoxide for Transplantation
Current Pharmaceutical Biotechnology Potential Use of Dendritic Cells for Anti-Atherosclerotic Therapy
Current Pharmaceutical Design Interleukin-10
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry K-Ras, Intestinal Homeostasis and Colon Cancer
Current Clinical Pharmacology Pharmacology of Voltage-Gated Proton Channels
Current Pharmaceutical Design Scutellarin Attenuates Microglia-Mediated Neuroinflammation and Promotes Astrogliosis in Cerebral Ischemia - A Therapeutic Consideration
Current Medicinal Chemistry Impact of Altered Early Infant Gut Microbiota Following Breastfeeding and Delivery Mode on Allergic Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Resveratrol: New Avenues for a Natural Compound in Neuroprotection
Current Pharmaceutical Design Dermal Delivery of Meloxicam Nanosuspensions based Gel: Optimization with Box Behnken Design Experiment Approach: Ex Vivo and In Vivo Study
Nanoscience & Nanotechnology-Asia The Endocannabinoid System and Multiple Sclerosis
Current Pharmaceutical Design New Drugs for Follicular Lymphoma in Older Adults
Anti-Cancer Agents in Medicinal Chemistry The Role of Anticoagulation in Cancer Patients: Facts and Figures
Anti-Cancer Agents in Medicinal Chemistry Outcomes of Anticoagulant Therapy with Low-Molecular-Weight Heparin (LMWH) and Warfarin for Thromboangiitis Obliterans (TAO)
Current Vascular Pharmacology Patent Selections
Recent Patents on Cardiovascular Drug Discovery Monoclonal Antibodies: A New Era in the Treatment of Non-Hodgkins Lymphoma
Current Pharmaceutical Biotechnology Ionic Liquids for Green Organic Synthesis
Current Organic Synthesis Mechanistic Systems Biology of Inflammatory Gene Expression in Airway Smooth Muscle as Tool for Asthma Drug Development
Current Drug Discovery Technologies